Autism CBD Trial On Children Advances As Israeli Company Enrolls First Five Patients
Portfolio Pulse from Jelena Martinovic
SciSparc Ltd. (NASDAQ:SPRC) has enrolled the first five patients in its clinical trial for a CBD-based treatment for autism spectrum disorder (ASD) in children. The trial, conducted at Soroka Medical Center in Israel, aims to assess the efficacy and safety of SciSparc's proprietary SCI-210 drug. The company plans to enroll 60 subjects and eventually sell the treatment in Israel and other countries.
August 20, 2024 | 7:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc Ltd. has enrolled the first five patients in its clinical trial for a CBD-based treatment for autism spectrum disorder in children. The trial's progress could impact the company's stock as it aims to sell the treatment in Israel and other countries.
The enrollment of patients in the clinical trial marks a significant step in the development of SciSparc's CBD-based treatment for ASD. Successful trial results could lead to regulatory approvals and market entry, potentially boosting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100